Expression of the p16<sup>INK4a</sup> tumor suppressor correlates with adverse clinical outcome in follicular lymphoma
Cheryl J. Foster, D.P. LeBrun, Phillip Farmer, Harriet Feilotter(University Health Network), Tara Baetz(Queen's University), R. Sidhu(Amgen (United States))
Cited by 0
Related Papers
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
|Annals of Oncology|2014|603
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
|Annals of Oncology|2013|220
Faecal lactoferrin – a novel test to differentiate between the irritable and inflamed bowel?
|Alimentary Pharmacology & Therapeutics|2010|57
Low rates of serious complications but high rates of hardware removal after high tibial osteotomy with Tomofix locking plate
|Knee Surgery Sports Traumatology Arthroscopy|2020|42